Insider Transactions in Q4 2022 at Biogen Inc. (BIIB)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2022
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
156
-6.59%
|
$45,084
$289.1 P/Share
|
|
Dec 08
2022
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
350
+12.88%
|
-
|
|
Dec 02
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
39
-1.39%
|
$11,622
$298.9 P/Share
|
|
Dec 02
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
131
+4.46%
|
-
|
|
Dec 02
2022
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
759
-11.3%
|
$226,182
$298.9 P/Share
|
|
Dec 02
2022
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,710
+19.51%
|
-
|
|
Nov 14
2022
|
Ginger Gregory EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
5,610
-49.55%
|
$1,683,000
$300.11 P/Share
|
|
Oct 27
2022
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,532
-12.31%
|
$1,548,960
$280.7 P/Share
|